Gerald Asin, MD
Internal Medicine · Paradise Valley, AZNPI 1770576365
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (58.2%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 18.1%. 2025 is the largest year on record at $16,017, 2.8 times the $5,698 reported in 2019. Among internal medicine clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,380 payments — averaging $31.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$8K
- Eisai Inc.$6K
- AbbVie$5K
- Novo Nordisk$3K
- Shionogi Inc$2K
- Lilly USA, LLC$2K
- plus $16K from 54 others
Across 24 payments — averaging $12,879 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$215K
- Merck$73K
- Abbott$21K
What the payments were for
- Consulting fees$11,94828%
- Speaking & faculty fees$450%
- Travel & lodging$5,41213%
- Food & beverage$25,00258%
- Education$4941%
- Gifts$590%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$42,959 in reported general payments places this provider in the 95th percentile of 2,212 internal medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 141 | $134,053 |
| OzempicSemaglutide | 117 | $129,369 |
| MounjaroTirzepatide | 103 | $123,051 |
| EliquisApixaban | 165 | $119,981 |
| FarxigaDapagliflozin Propanediol | 111 | $114,067 |
| MyrbetriqMirabegron | 96 | $81,097 |
| Tresiba Flextouch U-200Insulin Degludec | 59 | $62,051 |
| RybelsusSemaglutide | 32 | $56,178 |
| XareltoRivaroxaban | 49 | $51,396 |
| TrulicityDulaglutide | 29 | $37,028 |
| GemtesaVibegron | 36 | $32,309 |
| CreonLipase/Protease/Amylase | 17 | $29,057 |
| Xigduo XrDapaglifloz Propaned/Metformin | 21 | $24,424 |
| LinzessLinaclotide | 21 | $24,051 |
| JanuviaSitagliptin Phosphate | 14 | $20,944 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $3,004 | $185,548149 claims |
| Lilly USA, LLCMounjaro, Trulicity | $2,090 | $160,078132 claims |
| Boehringer IngelheimJardiance | $7,789 | $134,053141 claims |
| PfizerEliquis | $1,076 | $119,981165 claims |
| AstraZenecaFarxiga | $1,006 | $114,067111 claims |
| Astellas Pharma US IncMyrbetriq | $486 | $81,09796 claims |
| AbbVieCreon, Linzess, Synthroid | $5,419 | $63,465184 claims |
| Johnson & JohnsonXarelto | $881 | $51,39649 claims |
| GSKAnoro Ellipta, Trelegy Ellipta, Breo Ellipta | $879 | $33,94357 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $208 | $32,30936 claims |
| MerckJanuvia, Belsomra | $137 | $28,00430 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $793 | $18,87115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,212 internal medicine providers in Arizona.
Other internal medicine in Paradise Valley
- Kevin TheodorouParadise Valley$20K
- Frank LovecchioPhoenix$911K
- Nasser HajaigPhoenix$687K
- Rajesh JanardhananTucson$685K
- Mona SelejTucson$440K
- Kelly KrohnPhoenix$262K
- Jacque SokolovScottsdale$235K
- Paul StanderPhoenix$222K
- Howard GrossmanPhoenix$131K
- Christine HarterGlendale$127K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.